Full-Time
Senior Director
Safety Data Sciences
Posted on 9/10/2026
AbbVie
10,001+ employees
Global biopharmaceutical company developing medicines
Compensation Overview
$206.5k - $393k/yr
North Chicago, IL, USA
Hybrid
PharmD, PhD, MD
 Biology & Biotech |
|---|
Get referred to AbbVie
See people who can refer or advise you
- An advanced degree is required: MD, PharmD, or PhD.
- At least 15 years of experience in pharmacovigilance and drug safety, including comprehensive expertise across the product lifecycle from first-in-human studies through post-marketing.
- At least 8 years of leadership experience managing global teams, with demonstrated success driving impactful change.
- Ability to lead diverse teams and influence senior leadership across global patient safety, research and development, and the organization.
- Strong relationship management and communication skills, supported by emotional intelligence.
- Thorough understanding of global pharmacovigilance regulations, risk management, labelling, and the interconnectedness of safety science, real-world data, and drug development.
- Ability to lead, motivate, and inspire a diverse team located across multiple geographical locations.
- Lead a global team of more than 40 physicians, pharmacists, and healthcare professionals accountable for signal detection, safety surveillance, and aggregate safety data analysis across the portfolio.
- Set the strategic direction for signal detection and surveillance across development and marketed products.
- Guide integration of clinical trial data, spontaneous adverse event reports, real-world data, literature, electronic health records, and preclinical findings to identify, evaluate, and contextualize potential signals.
- Champion exploratory analytics, advanced visualization, automation, and artificial-intelligence-enabled capabilities while maintaining compliance with global pharmacovigilance regulations and company guardrails.
- Advance signal management capabilities through fit-for-purpose tools, technology, training, and mentorship.
- Translate evolving global pharmacovigilance requirements into effective internal processes, procedures, and standards that maintain compliance and support safety decision-making.
- Mentor and develop a diverse, multidisciplinary team while promoting professional growth, inclusive leadership, scientific excellence, and innovation.
- Partner with therapeutic-area heads to provide appropriate cross-functional Safety Data Sciences support for each therapeutic area within Global Patient Safety.
- Partner with the Safety Data Architect team to deliver optimized, technology-enabled signal management approaches for development products, including aligned strategies, monitoring communication channels, and safety-issue escalation and resolution protocols.
- Lead development and execution of pharmacovigilance deliverables, including safety assessments, regulatory responses, risk management plans, periodic safety update reports, and periodic adverse drug experience reports.
- Drive continuous process improvement across surveillance, signal management, and aggregate data analysis using data, technology, and stakeholder feedback.
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to AbbVie
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue hit $16.99 billion, up 10.2%, and adjusted EPS reached $3.65.
- FDA approved Decnupaz in May 2026, AbbVie’s first hematology ADC.
- European approvals for Rinvoq in vitiligo and alopecia expand 2026 commercial reach.
What critics are saying
- Imbruvica faced Medicare price cuts in 2026, accelerating oncology erosion and reimbursement pressure.
- Oncology revenue fell 2.4% in Q2 2026 as Imbruvica dropped 29.4%.
- Skyrizi-Rinvoq concentration leaves AbbVie vulnerable if one safety signal emerges.
What makes AbbVie unique
- AbbVie’s Skyrizi and Rinvoq generated enough growth to replace Humira by 2025.
- AbbVie now pairs immunology scale with oncology assets like Epkinly, Emrelis, and Decnupaz.
- Apogee’s 2026 deal adds late-stage IL-13 and TSLP antibodies for eczema and asthma.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 5%2 year growth
↑ 5%AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.
The Manufacturers Life Insurance Company acquired a $655.27 million stake in AbbVie Inc., according to its latest SEC Form 13F filing. Other institutional investors also increased their positions significantly during the same period. Norges Bank acquired a new $5.87 billion position, whilst Wellington Management Group boosted its holdings by 457.4%. AbbVie reported quarterly earnings per share of $3.65, exceeding forecasts, with revenue growth of 10.2% year over year. The company generated $16.99 billion in revenue last quarter, surpassing expectations. Equity analysts maintain a bullish outlook. Barclays, Wolfe Research, and BMO Capital Markets each set price targets of $300, with ratings of "overweight" or "outperform". The consensus rating is "Moderate Buy". Institutional investors currently hold 70.23% of AbbVie's shares, reflecting confidence in the biopharmaceutical company's strategy and performance.
AAPS PharmSci 360: CMC strategies, part 1. In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discussed how CMC review practices are evolving and what that means for manufacturing strategy. PharmTech spoke with Alfred Rumondor, PhD, CMC due diligence for external assets at AbbVie, and Swita Singh, PhD, Senior Director and Strategic CMC Leader at Bristol Myers Squibb, to learn more about their upcoming panel discussion, Navigating CMC Strategy in the Current Landscape, at, which is being held from October 25-28 in New Orleans. In part 1 of this 3-part interview, Rumondor and Singh discussed how chemistry, manufacturing, and controls (CMC) review practices are evolving and what that means for manufacturing strategy. Singh identified the most consequential shift as a move from informal, reviewer-dependent flexibility to formal, risk-based flexibility applied consistently across the product life cycle. She pointed to Operation TrailBlazer and updated phase 1 CMC guidance as examples, stating they are reducing required manufacturing data pre-investigational new drug application (IND). Singh also pointed out that cell and gene therapy programs no longer need 3 independent process performance qualification batches and can flex specifications for small-batch production. AI-driven tools and emerging credibility frameworks are reinforcing this trend by helping generate cleaner data packages for faster, more consistent regulatory decisions. Singh cautioned, however, that companies must build "risk justification muscle" rather than simply accepting flexibility at face value. Reduced requirements should be treated as deferral, not elimination, of data obligations; organizations need clear plans for when deferred data will be generated and which milestones trigger it. She emphasized investing early in comparability infrastructure, leveraging platform and prior-knowledge pathways, and engaging proactively with regulators. Rumondor addressed the pressure to compress development timelines. He argued the real question isn't whether compression is safe, but how to do it properly by working smarter rather than skipping steps. He cited premature form selection without adequate screening as a common shortcut that later may bring costly bridging and comparability studies, increasing both timeline and program risk. Compressed timelines are achievable, but only when teams rigorously plan the full development path upfront, according to Rumondor. About the speakers. Alfred Rumondor, PhD, is Director, Development Sciences Licensing and Acquisitions, at AbbVie. Dr. Swita Singh holds a Ph.D. in Pharmaceutical Sciences and brings over fifteen years of distinguished expertise in Chemistry, Manufacturing, and Controls (CMC) development across biologics, antibody drug conjugates, and small molecules, with a proven record of driving strategic initiatives, optimizing complex business processes, and leading cross-functional teams to achieve regulatory and operational excellence. Recognized for delivering innovative, end-to-end CMC strategies that guide programs from early clinical development through successful commercialization, she has cultivated talent and shaped organizational culture throughout her career, while her commitment to stakeholder communication and cross-functional collaboration has consistently advanced program objectives across the industry. Having built her expertise at Pfizer and Eli Lilly and Company, Dr. Singh currently serves at Bristol Myers Squibb (BMS), where she continues to lead CMC strategy in support of transformative therapeutic development.
AbbVie's experimental cancer drug etentamig achieved a 74% overall response rate in a pivotal Phase 3 trial for relapsed or refractory multiple myeloma, significantly outperforming standard treatments at 45.7%. The study also met its progression-free-survival endpoint. The drug remains investigational pending regulatory review. AbbVie's oncology division reported $1.65 billion in second-quarter revenue, down 1.5%, representing roughly 9.7% of total sales. Venclexta grew 11.6%, whilst Imbruvica declined 29.4%. AbbVie shares traded at $260.445. The company requires new growth drivers as its existing oncology portfolio faces mixed performance. Detailed safety and durability data have not yet been disclosed.
Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.